We also observed no significant difference in PTX3, the level of other biomarkers, and mPAP or PVR between patients treated with PAH-specific therapies and patients who were not so treated (PTX3: 5.94±3.52 ng/mL vs. 5.38±4.81 ng/mL, respectively, p = 0.405). Here, PTX3 is linked to pulmonary arterial hypertension.